{
    "id": 274,
    "fullName": "EGFR T790M",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR T790M is a gatekeeper mutation that lies within the ATP-binding pocket in the protein kinase domain of the Egfr protein (PMID: 20026433). T790M results in increased Egfr kinase activity, is transforming in culture (PMID: 30952700), and frequently occurrs as secondary somatic mutation that confers resistance to reversible tyrosine kinase inhibitors (PMID: 17671201, PMID: 18227510, PMID: 20026433).",
            "references": [
                {
                    "id": 442,
                    "pubMedId": 18227510,
                    "title": "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18227510"
                },
                {
                    "id": 12144,
                    "pubMedId": 17671201,
                    "title": "Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17671201"
                },
                {
                    "id": 443,
                    "pubMedId": 20026433,
                    "title": "Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20026433"
                },
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                }
            ]
        }
    ],
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "T790M",
    "createDate": "03/13/2014",
    "updateDate": "07/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 135938,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181378C>T",
        "cDna": "c.2369C>T",
        "protein": "p.T790M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Egfr in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).",
            "molecularProfile": {
                "id": 31248,
                "profileName": "EGFR T790M EGFR L858R EGFR over exp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15821,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, EGFR amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31243,
                "profileName": "EGFR T790M EGFR act mut EGFR amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17302,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in gradual tumor reduction and improved quality of life lasted for 1.5 years in a patient with metastatic non-small cell lung cancer harboring EGFR T790M, L858R, and A871G, TP53 R248W, and RB1 K844S (PMID: 31045832).",
            "molecularProfile": {
                "id": 32490,
                "profileName": "EGFR T790M EGFR L858R EGFR A871G TP53 R248W RB1 K844S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15348,
                    "pubMedId": 31045832,
                    "title": "Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9238,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9236,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 46,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CO-1686 has demonstrated safety and efficacy in NSCLC patients carrying EGFR T790M mutations (J Clin Oncol 31, 2013 (suppl; abstr 2524)).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 976,
                    "pubMedId": null,
                    "title": "First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.",
                    "url": "http://meetinglibrary.asco.org/content/117319-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3118,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3633,
                    "pubMedId": 25923550,
                    "title": "Rociletinib in EGFR-mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923550"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4350,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ASP8273 treatment resulted in partial response in 38% (15/40) and stable disease in 28% (11/40) of non-small cell lung carcinoma patients harboring EGFR T790M, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6005,
                    "pubMedId": null,
                    "title": "Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.",
                    "url": "http://meetinglibrary.asco.org/content/162561-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1379,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 990,
                "therapyName": "AV-412",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1110,
                    "pubMedId": 17888033,
                    "title": "Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17888033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12732,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase II clinical trials (AURA extension and AURA2), Tagrisso (osimertinib) treatment resulted in a central nervous system (CNS) overall response rate of 54% (24/50), including 6 complete responses, and a CNS disease control rate of 92% (46/50) in non-small cell lung cancer patients with CNS metatstases harboring EGFR T790M (PMID: 29293889; NCT01802632, NCT02094261).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10665,
                    "pubMedId": 29293889,
                    "title": "CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29293889"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12957,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines as subsequent therapy in patients with EGFR T790M-positive, metastatic non-small cell lung cancer who have progressed on Tarceva (erlotinib), Iressa (gefitinib), or Gilotrif (afatinib), and in patients who have progression with symptomatic brain metastases (NCCN.org).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3623,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I extension trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in in an objective response rate of 58% (115/119) and disease control rate of 92% in patients with EGFR-TKI resistant non-small cell lung cancer harboring EGFR T790M mutations (World Conf on Lung Cancer 2015. Abst MINI16.06).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3913,
                    "pubMedId": null,
                    "title": "AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study Phase II Extension Cohort.",
                    "url": "http://library.iaslc.org/virtual-library-search?product_id=1&author=Yang&category=&date=&session_type=&session=&presentation=&keyword=AURA"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15473,
                    "pubMedId": null,
                    "title": "Tagrisso (osimertinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17440,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring EGFR T790M (PMID: 30715168, PMID: 30285222; ESMO guidelines).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9600,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (AURA3), treatment with Tagrisso (osimertinib) resulted in an improved median progression-free survival of 10.1 months vs. 4.4 months with platinum plus pemetrexed, and an objective response rate of 71% (95% CI, 65 to 76) compared to 31% (95% CI, 24 to 40) with platinum plus pemetrexed therapy in patients with EGFR T790M-positive non-small cell lung cancer (PMID: 27959700; NCT02151981).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7315,
                    "pubMedId": 27959700,
                    "title": "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27959700"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 45,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tagrisso (osimertinib) demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 194,
                    "pubMedId": 24410791,
                    "title": "Novel agents and strategies for overcoming EGFR TKIs resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24410791"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2156,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tagrisso (osimertinib) treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549; NCT01802632).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2666,
                    "pubMedId": 25923549,
                    "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923549"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16691,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7049,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, BI 1482694 (HM61713) treatment resulted in a disease control rate of 90% (64/71), and objective response with a median duration of 8.3 months in 56% (40/71) of patients with EGFR tyrosine kinase inhibitor-resistant non-small cell lung carcinoma harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9055)).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6057,
                    "pubMedId": null,
                    "title": "BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.",
                    "url": "http://meetinglibrary.asco.org/content/164852-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 982,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16690,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13966,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alflutinib (AST2818) treatment resulted in an objective response rate of 58.3% (7/12) and a disease control rate of 91.7% (11/12) in patents with non-small cell lung cancer harboring EGFR T790M whose disease progressed on EGFR tyrosine kinase inhibitor therapy (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 6979,
                "therapyName": "Alflutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11392,
                    "pubMedId": null,
                    "title": "P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial",
                    "url": "https://www.jto.org/article/S1556-0864(17)32014-2/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3365,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 15% (4/27), stable disease in 56% (15/27), and progressive disease in 30% (8/27) of non-small cell lung carcinoma patients harboring an EGFR T790M mutation (PMID: 26354527).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3736,
                    "pubMedId": 26354527,
                    "title": "Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26354527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12772,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 14.3% (2/14) in non-small cell lung cancer patients harboring EGFR T790M, with a mean progression-free survival of 2.9 months, and an overall survival of 14.9 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3328,
                    "pubMedId": 26051236,
                    "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26051236"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11157,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR T790M demonstrated a response rate of 4.76% and disease control rate of 47.62%, and a median progression-free survival of 1.6 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9121,
                    "pubMedId": null,
                    "title": "Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186649.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16689,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6499,
                    "pubMedId": 27468240,
                    "title": "Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27468240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13964,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in decreased EGFR T790M allele frequency in cell free DNA of non-small cell lung carcinoma patients with acquired resistance to first generation Egfr tyrosine kinase inhibitor, and resulted in partial response or stable disease (PMID: 29626621).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Avitinib maleate",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11390,
                    "pubMedId": 29626621,
                    "title": "First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29626621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9118,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with Avitinib maleate (AC0010) (PMID: 27573423; NCT02274337).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Avitinib maleate",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6924,
                    "pubMedId": 27573423,
                    "title": "AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573423"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6995,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, EGF816 treatment resulted in an objective response rate of 44% (56/127), disease control rate of 91% (115/127), and an estimated progression-free survival of 9.2 months in non-small cell lung carcinoma patients harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9044); NCT02108964).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6004,
                    "pubMedId": null,
                    "title": "Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.",
                    "url": "http://meetinglibrary.asco.org/content/162578-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 987,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1005,
                "therapyName": "CUDC-101",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 43,
                    "pubMedId": 20388807,
                    "title": "CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20388807"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR T790M in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14954,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations, including EGFR T790M, demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 5229,
                "therapyName": "Amlexanox + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7601,
                    "pubMedId": 27287717,
                    "title": "IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27287717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6669,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4789,
                    "pubMedId": 26862733,
                    "title": "The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26862733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4877,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, HMPL-813 (Epitinib) demonstrated safety and preliminary efficacy in patients with NSCLC, including a patient with EGFR T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 3667,
                "therapyName": "Epitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4765,
                    "pubMedId": null,
                    "title": "Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/114269-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9230,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Alunbrig (brigatinib) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7043,
                    "pubMedId": 27836716,
                    "title": "Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27836716"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3083,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11690,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L844V"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11690,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L844V"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11690,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L844V"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11690,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L844V"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29165,
                "profileName": "EGFR L747_P753delinsS + EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29165,
                "profileName": "EGFR L747_P753delinsS + EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29165,
                "profileName": "EGFR L747_P753delinsS + EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29165,
                "profileName": "EGFR L747_P753delinsS + EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4495,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18261,
                "profileName": "EGFR L858R EGFR T790M NRAS Q61K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15796,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR L792H was identified in 1.76% (6/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 5 of the 6 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR L792H in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).",
            "molecularProfile": {
                "id": 31220,
                "profileName": "EGFR T790M EGFR L792H"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8186,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26185,
                "profileName": "EGFR L858R EGFR T790M PIK3CA G118D"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).",
            "molecularProfile": {
                "id": 26185,
                "profileName": "EGFR L858R EGFR T790M PIK3CA G118D"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8172,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26185,
                "profileName": "EGFR L858R EGFR T790M PIK3CA G118D"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8187,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26185,
                "profileName": "EGFR L858R EGFR T790M PIK3CA G118D"
            },
            "therapy": {
                "id": 1660,
                "therapyName": "BEZ235 + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 26185,
                "profileName": "EGFR L858R EGFR T790M PIK3CA G118D"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquired resistance to Rociletinib (CO-1686) treatment in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture was associated with EGFR amplification and reduced expression of EGFR E746_A750del and EGFR T790M, and proliferation and EGFR pathway signaling were maintained upon Rociletinib (CO-1686) treatment in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31154,
                "profileName": "EGFR amp EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15699,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Rociletinib (CO-1686)-resistant non-small cell lung cancer cell line harboring EGFR E746_A750del and EGFR T790M with EGFR amplification, which demonstrated reduced expression of EGFR E746_A750del and EGFR T790M relative to the parental cell line, exhibited reduced proliferation and increased apoptosis in response to combined Gilotrif (afatinib) and Erbitux (cetuximab) treatment relative to Gilotrif (afatinib) alone in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31154,
                "profileName": "EGFR amp EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 4190,
                "therapyName": "Afatinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15806,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, MET amplification was identified at disease progression in 26% (11/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31227,
                "profileName": "EGFR act mut EGFR T790M MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14450,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).",
            "molecularProfile": {
                "id": 30020,
                "profileName": "EGFR L858R EGFR T790M MET amp MET D1231Y"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3695,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3694,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15874,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR C797S was identified as an acquired mutation in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M at disease progression while on Olmutinib (HM61713) treatment (PMID: 26749488).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13881,
                    "pubMedId": 26749488,
                    "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26749488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5756,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17664,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) did not inhibit viability of patient-derived non-small cell lung cancer cells harboring EGFR C797S, EGFR exon 19 deletion, and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15498,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, acquired EGFR C797S mutations were identified in post-treatment samples of 6 non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M who progressed on Tagrisso (osimertinib) (PMID: 30228210).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13403,
                    "pubMedId": 30228210,
                    "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30228210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3692,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M  developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5755,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5747,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5760,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5754,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15869,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated an initial partial response to treatment with Nazartinib (CO-1686), however, demonstrated progression in the liver followed by the thorax, and progression in the thorax was coincident with emergence of an EGFR C797S mutation (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5746,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12680,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 28833,
                "profileName": "EGFR act mut EGFR C797S EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12671,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with ASP8273 resulted in a partial response in 41% (19/46) of non-small cell lung carcinoma patients co-harboring EGFR T790M and an EGFR activating mutation, demonstrating almost undetectable levels of the mutations in cell-free DNA (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR act mut EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTI-31 inhibited proliferation and migration and increased PD-L1 degradation in a non-small cell lung cancer cell line harboring an oncogenic EGFR mutation and secondary EGFR T790M mutation in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR act mut EGFR T790M"
            },
            "therapy": {
                "id": 8516,
                "therapyName": "MTI-31",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15515,
                    "pubMedId": 30796032,
                    "title": "A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30796032"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15170,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, EGFR T790M was identified at disease progression in 54% (19/35) of non-small cell lung cancer patients harboring sensitizing EGFR mutations (15 exon 19 deletion, 20 L858R) who received Iressa (gefitinib) as first-line treatment (PMID: 30268482).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR act mut EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12770,
                    "pubMedId": 30268482,
                    "title": "Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268482"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10689,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR act mut EGFR T790M"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8747,
                    "pubMedId": 28408243,
                    "title": "Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28408243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3263,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, the combination of Luminespib (AUY922) and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).",
            "molecularProfile": {
                "id": 13014,
                "profileName": "EGFR act mut EGFR T790M"
            },
            "therapy": {
                "id": 2799,
                "therapyName": "Erlotinib + Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3702,
                    "pubMedId": 25870087,
                    "title": "Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870087"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR P772_H773insGNP (referred to as D770_N771insNPG), and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).",
            "molecularProfile": {
                "id": 30023,
                "profileName": "EGFR C797S EGFR P772_H773insGNP EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3096,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11733,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3094,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11733,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12629,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) treatment resulted in disease progression after 3 months in a patient with lung adenocarcinoma harboring EGFR G719S and an acquired EGFR T790M, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).",
            "molecularProfile": {
                "id": 28794,
                "profileName": "EGFR G719S EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12627,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T790M was identified as an acquired mutation in the tumor of a patient with lung adenocarcinoma harboring EGFR G719S, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).",
            "molecularProfile": {
                "id": 28794,
                "profileName": "EGFR G719S EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17301,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Conmana (Icotinib) treatment resulted in initial response in a patient with metastatic non-small cell lung cancer harboring EGFR G719X, S768I, T790M, L858R, and L861Q, but resistance developed after 4 months of treatment (PMID: 31045832).",
            "molecularProfile": {
                "id": 32488,
                "profileName": "EGFR G719X EGFR S768I EGFR T790M EGFR L858R EGFR L861Q"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15348,
                    "pubMedId": 31045832,
                    "title": "Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10512,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",
            "molecularProfile": {
                "id": 27533,
                "profileName": "EGFR D770delinsGY EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8567,
                    "pubMedId": 28363995,
                    "title": "Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition of EGFR T790M was associated with resistance to Vizimpro (dacomitinib) in transformed cells expressing EGFR D770delinsGY (PMID: 28363995).",
            "molecularProfile": {
                "id": 27533,
                "profileName": "EGFR D770delinsGY EGFR T790M"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8567,
                    "pubMedId": 28363995,
                    "title": "Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15826,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Ebrr2 (Her2) in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).",
            "molecularProfile": {
                "id": 31249,
                "profileName": "EGFR T790M EGFR L858R ERBB2 over exp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10487,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545).",
            "molecularProfile": {
                "id": 27526,
                "profileName": "EGFR G719A EGFR L861Q EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8565,
                    "pubMedId": 28343545,
                    "title": "Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28343545"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10488,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) treatment resulted in partial response for over 8 months in a patient with lung adenocarcinoma harboring EGFR G719A, L861Q, and T790M that has progressed while on Tarceva (erlotinib) treatment (PMID: 28343545).",
            "molecularProfile": {
                "id": 27526,
                "profileName": "EGFR G719A EGFR L861Q EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8565,
                    "pubMedId": 28343545,
                    "title": "Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28343545"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13953,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del) and T790M, however, the disease progressed 20 months after treatment started, and EGFR P794L was identified by liquid biopsy at the time of progression (PMID: 29704676).",
            "molecularProfile": {
                "id": 29894,
                "profileName": "EGFR E746_S752del EGFR T790M EGFR P794L"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11378,
                    "pubMedId": 29704676,
                    "title": "Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29704676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13954,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in rapid clinical response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del), EGFR T790M and EGFR P794L (PMID: 29704676).",
            "molecularProfile": {
                "id": 29894,
                "profileName": "EGFR E746_S752del EGFR T790M EGFR P794L"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11378,
                    "pubMedId": 29704676,
                    "title": "Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29704676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8800,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26436,
                "profileName": "EGFR T790M ERBB2 over exp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26436,
                "profileName": "EGFR T790M ERBB2 over exp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11732,
                "profileName": "EGFR L858R EGFR Q791R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11732,
                "profileName": "EGFR L858R EGFR Q791R EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15824,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical study, EGFR L798I was identified at disease progression in a patients with non-small cell lung cancer harboring both EGFR T790M and EGFR exon 19 deletion treated with Rociletinib (CO-1686), consistent with structural modeling prediction in which EGFR L798I in cis with T790M interfered with Rociletinib (CO-1686) binding (PMID: 27283993).",
            "molecularProfile": {
                "id": 31247,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR L798I"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15811,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, ERBB2 (HER2) amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31239,
                "profileName": "EGFR T790M EGFR act mut ERBB2 amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11689,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L718Q"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3074,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11689,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L718Q"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11689,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L718Q"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3093,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11689,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR L718Q"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) treatment reduced proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13610,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3048,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16637,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T790M was identified in a patient with lung adenocarcinoma  harboring EGFR E746_A750del with resistance to Iressa (gefitinib) (PMID: 15737014).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1879,
                    "pubMedId": 15737014,
                    "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15737014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9054,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib)  inhibited tumor growth, and resulted in increased ERK inhibition and reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring both EGFR E746_A750del and EGFR T790M (PMID: 26036643).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 3351,
                "therapyName": "Trametinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6890,
                    "pubMedId": 26036643,
                    "title": "Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment did not reduce proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15700,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) treatment reduced proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture, and reduced tumor growth in cell line xenograft mouse models (PMID: 30322949).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13608,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3047,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del, who were found to have acquired EGFR T790M upon disease progression on Iressa (gefitinib) therapy, had rapid disease progression in response to Tarceva (erlotinib) therapy (PMID: 18981003).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9254,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 11380,
                "profileName": "EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11729,
                "profileName": "EGFR L858R EGFR L718Q EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11729,
                "profileName": "EGFR L858R EGFR L718Q EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11341,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).",
            "molecularProfile": {
                "id": 27962,
                "profileName": "EGFR T790M EGFR mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9243,
                    "pubMedId": 28407039,
                    "title": "Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28407039"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17639,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival of 6.4 months in a patient with non-small cell lung cancer harboring EGFR A763_Y764insFQEA and EGFR T790M (PMID: 31208370).",
            "molecularProfile": {
                "id": 32706,
                "profileName": "EGFR A763_Y764insFQEA EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15706,
                    "pubMedId": 31208370,
                    "title": "EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31208370"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15823,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E545K was identified in 4 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31245,
                "profileName": "EGFR T790M EGFR act mut PIK3CA E545K"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S and EGFR T790M were sensitive to treatment with OBX1-012 in culture, demonstrating decreased cell viability (PMID: 29754184).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR C797S EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3053,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP, who was found to have acquired an EGFR T790M mutation upon disease progression on Iressa (gefitinib), had rapid disease progress in response Tarceva (erlotinib) therapy (PMID: 18981003).",
            "molecularProfile": {
                "id": 11384,
                "profileName": "EGFR L747_T751delinsP EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3051,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that developed resistance to Iressa (gefitinib) was found to have acquired an EGFR T790M mutation (PMID: 18981003).",
            "molecularProfile": {
                "id": 11384,
                "profileName": "EGFR L747_T751delinsP EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14448,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14449,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9923,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578).",
            "molecularProfile": {
                "id": 27160,
                "profileName": "EGFR G719A EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7760,
                    "pubMedId": 27913578,
                    "title": "Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27913578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15777,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15776,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15794,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tagrisso (osimertinib) and Erbitux (cetuximab) improved growth inhibition of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture compared to Tagrisso (osimertinib) alone (PMID: 29857056).",
            "molecularProfile": {
                "id": 31213,
                "profileName": "EGFR T790M EGFR L858R EGFR L792H"
            },
            "therapy": {
                "id": 7737,
                "therapyName": "Cetuximab + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15879,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a single patient with lung adenocarcinoma harboring an EGFR exon 19 deletion (E746_S752delinsV) and EGFR T790M was found to have acquired, via cell free DNA testing, an EGFR G724S mutation upon disease progression after 1 year of Tagrisso (osimertinib) therapy (PMID: 30588029).",
            "molecularProfile": {
                "id": 31308,
                "profileName": "EGFR G724S EGFR E746_S752delinsV EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13940,
                    "pubMedId": 30588029,
                    "title": "Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30588029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4494,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18240,
                "profileName": "EGFR exon 19 del EGFR T790M NRAS Q61K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8802,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9246,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, emergence of MET amplification was identified in 26% (28/43) of EGFR T790M-positive non-small cell lung cancer patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8801,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15873,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Olmutinib (HM61713) resulted in partial response after 2 cycles of treatment and was continued for 17 months until disease progression in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M (PMID: 26749488).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13881,
                    "pubMedId": 26749488,
                    "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26749488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13952,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Iressa (gefitinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion, however, the disease progressed 3 years after initial treatment and EGFR T790M was identified at the time of progression (PMID: 29704676).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11378,
                    "pubMedId": 29704676,
                    "title": "Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29704676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17623,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11751,
                    "pubMedId": 29858027,
                    "title": "Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29858027"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5937,
                "therapyName": "Osimertinib + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5938,
                "therapyName": "Osimertinib + PF-573228 + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14489,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del and EGFR T790M , resistant to Iressa (gefitinib) and Tarceva (erlotinib), were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro (PMID: 29754184).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4912,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients treated with Gilotrif (afatinib) that acquired resistance, with 9 of those patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4789,
                    "pubMedId": 26862733,
                    "title": "The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26862733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3929,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung cancer cell lines harboring both EGFR T790M and EGFR exon 19 deletion mutations, and decreased tumor size in xenograft models (PMID: 26090892).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14129,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4379,
                "therapyName": "Osimertinib + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11473,
                    "pubMedId": null,
                    "title": "Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.",
                    "url": "https://meetinglibrary.asco.org/record/160827/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13965,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Avitinib maleate",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11390,
                    "pubMedId": 29626621,
                    "title": "First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29626621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5936,
                "therapyName": "GSK2334470 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16692,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 83% (5/6) of non-small cell lung cancer patients harboring EGFR exon 19 deletions that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3120,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3633,
                    "pubMedId": 25923550,
                    "title": "Rociletinib in EGFR-mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923550"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung cancer cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17666,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Lazertinib (YH25448) treatment resulted in a 49.3% reduction of intracranial tumor and a 12.7% reduction of the extracranial tumor in a patient with non-small cell lung cancer harboring both EGFR exon 19 deletion mation and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5939,
                "therapyName": "Bosutinib + Osimertinib + PF-573228",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15867,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686) (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2157,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tagrisso (osimertinib) treatment resulted in a response rate of 64% (49/77) in non-small cell lung cancer patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549; NCT01802632).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2666,
                    "pubMedId": 25923549,
                    "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923549"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8969,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) obtained through a Phase I/II trial (AURA) resulted in a partial response and stable disease of brain metastases in a non-small cell lung cancer patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396; NCT01802632).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6826,
                    "pubMedId": 27435396,
                    "title": "Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27435396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17632,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment-naive non-small cell lung cancer patients harboring both EGFR exon 19 deletion mutations and ultra-low level EGFR T790M as detected by ddPCR demonstrated improved progression-free survival (39.5 vs 11.7 months, p=0.001) after first-generation tyrosine kinase inhibitor therapy compared to patients who did not harbor both mutations (PMID: 30936123).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15701,
                    "pubMedId": 30936123,
                    "title": "Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30936123"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited viability of patient-derived cells and a cell line of non-small cell lung cancer harboring both EGFR T790M and an EGFR exon 19 deletion mutation, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5748,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11303,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR harboring both exon 19 deletion and T790M in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing both EGFR T790M and an EGFR exon 19 deletion mutation (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5750,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3056,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M, who was found to have acquired an EGFR T790M mutation upon disease progression on Iressa (gefitinib), had rapid disease progression in response to Tarceva (erlotinib) therapy (PMID: 18981003).",
            "molecularProfile": {
                "id": 11381,
                "profileName": "EGFR L747_S752del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3055,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance after an initial response was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).",
            "molecularProfile": {
                "id": 11381,
                "profileName": "EGFR L747_S752del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16836,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of non-small cell lung cancer cell lines harboring EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models, and inhibited tumor growth in a patient-derived xenograft (PDX) model (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8204,
                "therapyName": "TQB3804",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14950,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16835,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of transformed cells expressing EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8204,
                "therapyName": "TQB3804",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14950,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7589,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 25912,
                "profileName": "EGFR I941R EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15797,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR G796R was identified in 0.59% (2/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 1 of the 2 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR G796R in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).",
            "molecularProfile": {
                "id": 31221,
                "profileName": "EGFR T790M EGFR G796R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14447,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).",
            "molecularProfile": {
                "id": 30017,
                "profileName": "EGFR L858R EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14446,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).",
            "molecularProfile": {
                "id": 30017,
                "profileName": "EGFR L858R EGFR T790M MET amp"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3087,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11730,
                "profileName": "EGFR L858R EGFR L844V EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3082,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11730,
                "profileName": "EGFR L858R EGFR L844V EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15822,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E542K was identified in 3 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31244,
                "profileName": "EGFR T790M EGFR act mut PIK3CA E542K"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L747_P753delinsS, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L858R, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3696,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266)",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14492,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3697,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266)",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15781,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15788,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15787,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792HG796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17661,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr signaling and viability of patient-derived cells and a cell line of non-small cell lung cancer harboring both EGFR T790M and EGFR L858R in culture, resulted in tumor shrinkage and inhibition of intracranial tumor growth in cell line xenograft models (PMID: 30670498).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9113,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring the double mutation, EGFR L858R and EGFR T790M, demonstrated sensitivity to treatment with Avitinib maleate (AC0010), resulting in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Avitinib maleate",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6924,
                    "pubMedId": 27573423,
                    "title": "AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573423"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14019,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Avitinib maleate",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11390,
                    "pubMedId": 29626621,
                    "title": "First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29626621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4911,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, acquired EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib), with 10 of those patients harboring EGFR L858R as their primary EGFR mutation (PMID: 26862733).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4789,
                    "pubMedId": 26862733,
                    "title": "The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26862733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13612,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3054,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3592,
                    "pubMedId": 18199554,
                    "title": "Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18199554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2294,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ganetespib and Gilotrif (afatinib) demonstrated improved antitumor activity compared to either agent alone in  cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2801,
                "therapyName": "Afatinib + Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17665,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Lazertinib (YH25448) treatment resulted in 51% tumor reduction after 6 weeks of treatment in a patient with non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9052,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) resulted in tumor regression, and decreased tumor rebound and increased survival compared to WZ4002 alone in non-small cell lung cancer mouse models expressing EGFR L858R and EGFR T790M (PMID: 26036643).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 3351,
                "therapyName": "Trametinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6890,
                    "pubMedId": 26036643,
                    "title": "Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7586,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6653,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed  after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4190,
                "therapyName": "Afatinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5721,
                    "pubMedId": 26341921,
                    "title": "Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Na\u00efve EGFR L858R-Induced Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341921"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7504,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3001,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2911,
                "therapyName": "EKI-285",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9234,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1380,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 990,
                "therapyName": "AV-412",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1110,
                    "pubMedId": 17888033,
                    "title": "Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17888033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17237,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR L858R and T790M in culture, resulted in tumor growth inhibition and regression in cell line xenograft and patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 8430,
                "therapyName": "DZD9008",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15248,
                    "pubMedId": null,
                    "title": "DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/7519"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7506,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, and resulted in durable response following treatment cessation (PMID: 27216193).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4502,
                "therapyName": "JNJ-61186372 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13968,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and down stream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring both EGFR L858R and T790M (PMID: 26375053).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11393,
                    "pubMedId": 26375053,
                    "title": "Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13975,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) did not inhibit Egfr activation and growth of non-small cell lung cancer cells harboring EGFR L858R and T790M in culture, but delayed the emergence of resistance in cell line xenograft models compared to EGFR tyrosine kinase inhibitors (PMID: 19447865).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11395,
                    "pubMedId": 19447865,
                    "title": "Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19447865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2158,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tagrisso (osimertinib) treatment resulted in a response rate of 57% (24/42) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549; NCT01802632).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2666,
                    "pubMedId": 25923549,
                    "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923549"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8972,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) obtained through a Phase I/II trial (AURA) resulted in a partial response and stable disease of brain metastases in a non-small cell lung cancer patient harboring EGFR L858R and a secondary resistance mutation, EGFR T790M, which occurred post Tarceva (erlotinib) therapy (PMID: 27435396; NCT01802632).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6826,
                    "pubMedId": 27435396,
                    "title": "Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27435396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8526,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Rapamune (sirolimus) to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment restored sensitivity in transgenic animal models of lung adenocarcinoma driven by EGFR L858R and T790M that acquired resistance to the combination treatment, resulted in tumor shrinkage (PMID: 24813888).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4764,
                "therapyName": "Afatinib + Cetuximab + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4088,
                    "pubMedId": 24813888,
                    "title": "Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24813888"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3119,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3633,
                    "pubMedId": 25923550,
                    "title": "Rociletinib in EGFR-mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923550"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9486,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3931,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13970,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Imbruvica (ibrutinib) and Mekinist (trametinib) combination treatment enhanced growth inhibition of non-small cell lung cancer cells harboring EGFR L858R and T790M compared to monotherapy in culture, but did not improve tumor suppression in cell line xenograft models (PMID: 26375053).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 6980,
                "therapyName": "Ibrutinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11393,
                    "pubMedId": 26375053,
                    "title": "Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing both EGFR L858R and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13614,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2997,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3134,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3641,
                    "pubMedId": 19238632,
                    "title": "Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19238632"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14130,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4379,
                "therapyName": "Osimertinib + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11473,
                    "pubMedId": null,
                    "title": "Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.",
                    "url": "https://meetinglibrary.asco.org/record/160827/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of a lung cancer cell line harboring EGFR L858R and EGFR T790M in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16561,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer (NSCLC) patient harboring EGFR L858R and T790M that had failed prior EGFR tyrosine kinase inhibitor therapy demonstrated 49% tumor shrinkage following treatment with TAS-121, and in preclinical experiments, TAS-121 inhibited EGFR signaling and proliferation of a NSCLC cell line harboring EGFR L858R and T790M in culture and inhibited tumor growth and improved survival in xenograft models (PMID: 30872380).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 8103,
                "therapyName": "TAS-121",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14625,
                    "pubMedId": 30872380,
                    "title": "TAS-121, a selective mutant EGFR inhibitor, shows activity against tumors expressing various EGFR mutations including T790M and uncommon mutations G719X.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30872380"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6652,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5721,
                    "pubMedId": 26341921,
                    "title": "Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Na\u00efve EGFR L858R-Induced Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341921"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17622,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11751,
                    "pubMedId": 29858027,
                    "title": "Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29858027"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1705,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1879,
                    "pubMedId": 15737014,
                    "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15737014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6668,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5727,
                    "pubMedId": 22263058,
                    "title": "T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22263058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2293,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2802,
                "therapyName": "Erlotinib + Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2971,
                    "pubMedId": 25077897,
                    "title": "The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25077897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5650,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring both EGFR L858R and EGFR T790M in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring both EGFR L858R and EGFR T790M (PMID: 26825170).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5135,
                    "pubMedId": 26825170,
                    "title": "EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26825170"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14486,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR L858R and EGFR T790M were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3898,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) and Nerlynx (neratinib) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 3379,
                "therapyName": "Gedatolisib + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4501,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R and EGFR T790M that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31213,
            "profileName": "EGFR T790M EGFR L858R EGFR L792H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32490,
            "profileName": "EGFR T790M EGFR L858R EGFR A871G TP53 R248W RB1 K844S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27160,
            "profileName": "EGFR G719A EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31243,
            "profileName": "EGFR T790M EGFR act mut EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27962,
            "profileName": "EGFR T790M EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31220,
            "profileName": "EGFR T790M EGFR L792H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30017,
            "profileName": "EGFR L858R EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 370,
            "profileName": "EGFR T790M",
            "profileTreatmentApproaches": [
                {
                    "id": 3720,
                    "name": "PF-06747775",
                    "profileName": "EGFR T790M"
                },
                {
                    "id": 71,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR T790M"
                }
            ]
        },
        {
            "id": 31154,
            "profileName": "EGFR amp EGFR E746_A750del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30024,
            "profileName": "EGFR P772_H773insGNP EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13014,
            "profileName": "EGFR act mut EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11729,
            "profileName": "EGFR L858R EGFR L718Q EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31249,
            "profileName": "EGFR T790M EGFR L858R ERBB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18261,
            "profileName": "EGFR L858R EGFR T790M NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11688,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27526,
            "profileName": "EGFR G719A EGFR L861Q EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27945,
            "profileName": "EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11380,
            "profileName": "EGFR E746_A750del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31244,
            "profileName": "EGFR T790M EGFR act mut PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11381,
            "profileName": "EGFR L747_S752del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11689,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR L718Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31247,
            "profileName": "EGFR exon 19 del EGFR T790M EGFR L798I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28833,
            "profileName": "EGFR act mut EGFR C797S EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14859,
            "profileName": "EGFR C797S EGFR L858R EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28794,
            "profileName": "EGFR G719S EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26437,
            "profileName": "EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31248,
            "profileName": "EGFR T790M EGFR L858R EGFR over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26185,
            "profileName": "EGFR L858R EGFR T790M PIK3CA G118D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26436,
            "profileName": "EGFR T790M ERBB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18241,
            "profileName": "EGFR exon 19 del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30018,
            "profileName": "EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11732,
            "profileName": "EGFR L858R EGFR Q791R EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30025,
            "profileName": "EGFR C797S EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30020,
            "profileName": "EGFR L858R EGFR T790M MET amp MET D1231Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11733,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11384,
            "profileName": "EGFR L747_T751delinsP EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28797,
            "profileName": "EGFR C797S EGFR L747_P753delinsS EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29894,
            "profileName": "EGFR E746_S752del EGFR T790M EGFR P794L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32488,
            "profileName": "EGFR G719X EGFR S768I EGFR T790M EGFR L858R EGFR L861Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31221,
            "profileName": "EGFR T790M EGFR G796R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31245,
            "profileName": "EGFR T790M EGFR act mut PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11690,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR L844V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31227,
            "profileName": "EGFR act mut EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2422,
            "profileName": "EGFR L858R EGFR T790M",
            "profileTreatmentApproaches": [
                {
                    "id": 170,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR L858R EGFR T790M"
                }
            ]
        },
        {
            "id": 18240,
            "profileName": "EGFR exon 19 del EGFR T790M NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31308,
            "profileName": "EGFR G724S EGFR E746_S752delinsV EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30023,
            "profileName": "EGFR C797S EGFR P772_H773insGNP EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11730,
            "profileName": "EGFR L858R EGFR L844V EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31214,
            "profileName": "EGFR T790M EGFR G796R EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14858,
            "profileName": "EGFR C797S EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29165,
            "profileName": "EGFR L747_P753delinsS + EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27533,
            "profileName": "EGFR D770delinsGY EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25912,
            "profileName": "EGFR I941R EGFR L858R EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32706,
            "profileName": "EGFR A763_Y764insFQEA EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31239,
            "profileName": "EGFR T790M EGFR act mut ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135938,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181378C>T",
            "cDna": "c.2369C>T",
            "protein": "p.T790M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}